Johan A. Dobber

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

Andy C. Rawstron, Claudia Fazi, Andreas Agathangelidis et al. · Leukemia · 2015 · 241 citations · Full text

Medicine, Hematology, Oncology +17

Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

Iris de Weerdt, Tom Hofland, Renate de Boer et al. · Blood Advances · 2019 · 107 citations · Full text

Life Sciences, Hematology, Immunology +17

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

Arnon P. Kater, Mark‐David Levin, Julie Dubois et al. · The Lancet Oncology · 2022 · 58 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial

Sabina Kersting, Julie Dubois, Kazem Nasserinejad et al. · The Lancet Haematology · 2022 · 31 citations · Full text

Medicine, Hematology, Pharmacology +3

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Lina van der Straten, Claudia A.M. Stege, Sabina Kersting et al. · Blood · 2023 · 28 citations · Full text

Medicine, Geriatric Medicine, Pharmacotherapy +6